MEDVi vs Mochi Health: November 2026 prices compared
As of November 20, 2026, neither MEDVi nor Mochi Health printed a month-to-month compounded price that applies at the maintenance dose, so this page compares what each did show and how each bills, without a price verdict.
Released · Last reviewed · how we verify
MEDVi and Mochi Health, measure by measure
| Measure | MEDVi | Mochi Health |
|---|---|---|
| Tirzepatide, month to month | — | from $169 (per month, starting-dose price) |
| Tirzepatide, lowest printed | — | $139 ($90 starting dose + $49 membership on a 12-month plan) |
| Semaglutide, month to month | — | from $139 (per month, starting-dose price) |
| Semaglutide, lowest printed | — | $109 ($60 starting dose + $49 membership on a 12-month plan) |
| Dose pricing | not confirmed | priced by dose or not stated |
| Membership or program fee | not confirmed | about $79 a month |
| Computed score | 0 of 40 (position 21 of 27) | 8 of 40 (position 18 of 27) |
| FDA warning letters | 721455 (2026-02-20) | none listed |
| November 20 read | not readable Nov 20 | first-party read, changed |
Strengths and limitations: which fits whom
MEDVi cannot be judged on price this month because its page could not be read on November 20, 2026. Mochi Health prices by dose, so its printed figure covers the first months; budget for a higher maintenance-dose price. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
What changed since August
The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.
| Program | Medication | August 5–10, 2026 | November 20, 2026 |
|---|---|---|---|
| Mochi Health | tirzepatide | — | from $169 |
| Mochi Health | semaglutide | — | from $139 |
Regulatory record
FDA’s warning-letter index lists warning letter 721455 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to MEDVi; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, MEDVi or Mochi Health?
Neither printed a comparable month-to-month price on November 20, 2026, so there is no like-for-like answer this month.
Do MEDVi and Mochi Health charge a membership fee?
MEDVi: not confirmed on November 20, 2026; Mochi Health: about $79 a month on top of medication. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are MEDVi and Mochi Health medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- MEDVi pricing page (not readable on November 20, 2026)
- Mochi Health pricing page (read November 20, 2026)
- FDA warning letter 721455 to MEDVi (dated 2026-02-20, posted 2026-03-03)